Forskning
Udskriv Udskriv
Switch language
Region Hovedstaden - en del af Københavns Universitetshospital
Udgivet

Diabetic macular oedema treated with intravitreal anti-vascular endothelial growth factor - 2-4 years follow-up of visual acuity and retinal thickness in 566 patients following Danish national guidelines

Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

DOI

  1. The tolerance of anisometropia

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  2. Loss of retinal tension and permanent decrease in retinal function: a new porcine model of rhegmatogenous retinal detachment

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  3. Prevalence and histopathological signatures of optic disc drusen based on microscopy of 1713 enucleated eyes

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  1. Pupillary light responses in type 1 and type 2 diabetics with and without retinopathy

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  2. Cohort Profile: The Copenhagen Child Cohort Study (CCC2000)

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  3. Retinal arteriolar wall-to-lumen ratios at 16-17 years in the Copenhagen Child Cohort 2000 Study

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

Vis graf over relationer

PURPOSE: To investigate long-term functional and anatomical outcomes, discontinuation patterns, drug switching and rates of nonimprovement in patients treated with ranibizumab pro re nata (PRN) regimen for diabetic macular oedema (DME) according to the Danish national guidelines.

METHODS: Retrospective cohort study of 566 eyes in 566 patients with centre-involved DME who started intravitreal treatment with ranibizumab between January 2011 and December 2013 in the Greater Copenhagen region. Data were retrieved from a database and patient records between January 2011 and March 2016 and analysed using mixed-model statistics.

RESULTS: At the conclusion of follow-up, 24.6% were in active ranibizumab follow-up, 25.4% had switched to other intravitreal pharmacotherapy, 31.6% had been discontinued because of disease stability, 13.8% had been lost to follow-up, 1.4% had been discontinued because of low visual acuity (VA), and 3.2% had died. At baseline, mean best-corrected visual acuity (BCVA) and mean central subfield thickness (CST) were 64.9 (±15.0) letters and 400.2 (±120.3) μm. Mean change in BCVA and mean change in CST from baseline to 3, 12, 24, 36 and 48 months of follow-up were +3.9, +3.5, +2.7, +1.8, +2.3 letters and -97.4, -102.6, -106.9, -105.9, -131.6 μm, respectively. Mean number of injections was 6.1 in year 1 and 1.8 in year 4. In 93 patients, drug switching to aflibercept showed no difference between the two drugs on BCVA or CST. In 79 patients, CST decreased <10% compared to baseline during the first year.

CONCLUSION: In a single-centre clinical setting, 566 patients treated for DME with ranibizumab according to the Danish national guidelines were followed for up to 4 years. Best-corrected visual acuity (BCVA) outcomes are in the low end of clinical studies, but studied on a wider population and achieved with fewer injections.

OriginalsprogEngelsk
TidsskriftActa Ophthalmologica
Vol/bind96
Udgave nummer3
Sider (fra-til)267-278
Antal sider11
ISSN1755-375X
DOI
StatusUdgivet - maj 2018

ID: 52168424